← Back to Search

Dietary Supplement

Beta-glucan for Hematopoietic Stem Cell Transplant

Phase 1 & 2

Waitlist Available

Led By Wendy Dahl, PhD

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Awards & highlights

Study Summary

This trial tests if supplementing with a yeast-derived β-glucan can reduce fatigue in multiple myeloma survivors who had an autologous HCT. Changes in fatigue symptoms are monitored over 8 weeks.

Eligible Conditions

Hematopoietic Stem Cell Transplant

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in fatigue as assessed by Brief Fatigue Inventory (BFI) tool

Secondary outcome measures

Bone and Bones

Change in General Sleep Disturbances Scale (GSDS) score

Change in Global07, from PROMIS® Numeric Rating Scale v.1.0 - Pain Intensity 1a plus PAININ20, from PROMIS - Ca Item Bank v1.1 - Pain Interference score

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Beta-glucanExperimental Treatment1 Intervention

500 mg/d of beta-glucan

Group II: PlaceboPlacebo Group1 Intervention

500 mg/d of cellulose

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor

1,342 Previous Clinical Trials

715,667 Total Patients Enrolled

Lallemand Bio-IngredientsOTHER

3 Previous Clinical Trials

85 Total Patients Enrolled

Wendy Dahl, PhDPrincipal InvestigatorUniversity of Florida

2 Previous Clinical Trials

255 Total Patients Enrolled

Media Library

Beta-glucan (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05524688 — Phase 1 & 2

Hematopoietic Stem Cell Transplant Research Study Groups: Beta-glucan, Placebo

Hematopoietic Stem Cell Transplant Clinical Trial 2023: Beta-glucan Highlights & Side Effects. Trial Name: NCT05524688 — Phase 1 & 2

Beta-glucan (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05524688 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for enrollment into this investigation senior citizens?

"This medical study is seeking out participants who are at least 18 years of age, but younger than 99."

Answered by AI

Could I be a suitable participant in this research study?

"To partake in this clinical trial, participants must have undergone a hematopoietic stem cell transplant and fall between the ages of 18-99. Currently, around 80 individuals are being sought after for recruitment."

Answered by AI

Are there any vacancies still available for individuals to join this clinical experiment?

"Per clinicaltrials.gov, recruitment for this trial is currently underway; it was initially listed on February 10th 2023 and its details were last modified May 23rd of the same year."

Answered by AI

How many people have enrolled in this research endeavor?

"Affirmative. Clinicaltrials.gov data indicates that this clinical trial is currently recruiting and was originally posted on February 10th 2023. The study seeks to recruit 80 patients from 1 medical center, with the last edit occurring May 23rd 2023."

Answered by AI

What results are researchers hoping to obtain with this experiment?

"This 8-week trial will measure its primary outcome, the Brief Fatigue Inventory (BFI), along with secondary outcomes such as Change in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT) score for quality of life assessment, General Sleep Disturbance Scale (GSDS) to record sleep disturbances, and frequency of adverse events."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Beta-glucan and Fatigue in HSCT Survivors

2023. "Beta-glucan and Fatigue in HSCT Survivors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05524688.